By Rob Otman Taro (NYSE: TARO) is a mid cap company that operates within the pharmaceuticals industry. Its market cap is $5 billion today and the total one-year return is -3.01% for shareholders.
Taro stock is underperforming the market. It’s beaten down, but it reports earnings soon. So is it a good time to buy? To answer this question we’ve turned to the Investment U Stock Grader. Our research team built this system to diagnose the financial health of a company.
Our system looks at six key metrics…
[iu-adbox]
✗ Earnings-per-Share (EPS) Growth: Taro reported a recent EPS growth rate of -86.85%. That’s below the pharmaceuticals …read more
